Abstract
Background: Since 2011, triple therapy with the HCV protease inhibitor boceprevir (BOC) is widely used as standard of care for patients (pts) with chronic HCV G1 infection. The present interim analysis of the German NOVUS observational study was aimed to compare the efficacy of BOC triple therapy in previously untreated and previously treated patients in German real-world and, in particular, to compare the virologic outcome of pts who achieve an early virologic response (EVR) at treatment week (TW) 8.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
